Navegar por autor "Casal Rubio, Joaquín"

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study

2013- Afonso Afonso, Francisco Javier; Lazaro Quintela, Martín; Vázquez Estévez, Sergio; Campos Balea, Begoña; Barón Duarte, Francisco Javier; [et al.]

Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer

2013- Candamio Folgar, Sonia; Gallardo Martín , Maria Elena; Campos Balea, Begoña; Álvarez Gómez, Elena; Quintero Aldana, Guillermo; [et al.]

Docetaxel (D) and cisplatin (C) induction chemotherapy followed by biweekly D and C with concurrent thoracic radiotherapy for stage iii nonsmall cell lung cancer (NSCLC). A galician lung cancer group study.

2011- Lazaro Quintela, Martín; Vázquez Estévez, Sergio; Varela Ferreiro, Silvia; Campos Balea, Begoña; Casal Rubio, Joaquín [et al.]

Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors

2015- Lazaro Quintela, Martín; Areses Manrique, María Carmen; Huidobro Vence, Gerardo; Villanueva Silva, María José; Casal Rubio, Joaquín [et al.]

Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy

2019- RUIZ BAÑOBRE, JUAN; Areses Manrique, María Carmen; Mosquera-Martinez, J.; Cortegoso Mosquera, Alexandra Sabela; Afonso-Afonso, F. J.; [et al.]

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

2015- Casal Rubio, Joaquín

Full-dose Cisplatin and Oral Vinorelbine Concomitant with Radiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: A Multi-center Phase II Study

2014- Firvida Perez, Jose Luis; Lazaro Quintela, Martín; Casal Rubio, Joaquín

Induction chemotherapy with docetaxel (D) and cisplatin (C) followed by concurrent thoracic radiotherapy with biweekly d and C for stage III non-small cell lung cancer (NSCLC) - A galician lung cancer group study

2011- Anido Herranz, Urbano; Firvida Perez, Jose Luis; Lazaro Quintela, Martín; Calvo Crespo, Patricia; Vázquez Estévez, Sergio; [et al.]

Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study)

2019- Provencio, Mariano; Carcereny, Enric; Rodriguez-Abreu, Delvys; Lopez-Castro, Rafael; Guirado, Maria; [et al.]

Lung cancer symptoms at diagnosis: results of a nationwide registry study

2020- Ruano Raviña, Alberto; Provencio, Mariano; Calvo de Juan, Virginia; Carcereny, Enric; Moran, Teresa; [et al.]

Paclitaxel and irinotecan in platinum refractory or resistant patients with small cell lung cancer: Experience from the Galician Lung Cancer Group

2013- Afonso Afonso, Francisco Javier; Firvida Perez, Jose Luis; Areses Manrique, María Carmen; Vázquez Estévez, Sergio; Campos Balea, Begoña; [et al.]

PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis

2020- García González, Jorge José; RUIZ BAÑOBRE, JUAN; Afonso Afonso, Francisco Javier; Amenedo-Gancedo, Margarita; Areses Manrique, María Carmen; [et al.]

Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer

2015- Gallardo Martín , Maria Elena; Fernández Montes, Ana; Varela Ferreiro, Silvia; Campos Balea, Begoña; Álvarez Gómez, Elena; [et al.]

Repositorio digital RUNA

Navegar por autor "Casal Rubio, Joaquín"

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study ﻿

Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer ﻿

Docetaxel (D) and cisplatin (C) induction chemotherapy followed by biweekly D and C with concurrent thoracic radiotherapy for stage iii nonsmall cell lung cancer (NSCLC). A galician lung cancer group study. ﻿

Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors ﻿

Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy ﻿

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer ﻿

Full-dose Cisplatin and Oral Vinorelbine Concomitant with Radiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: A Multi-center Phase II Study ﻿

Induction chemotherapy with docetaxel (D) and cisplatin (C) followed by concurrent thoracic radiotherapy with biweekly d and C for stage III non-small cell lung cancer (NSCLC) - A galician lung cancer group study ﻿

Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study) ﻿

Lung cancer symptoms at diagnosis: results of a nationwide registry study ﻿

Paclitaxel and irinotecan in platinum refractory or resistant patients with small cell lung cancer: Experience from the Galician Lung Cancer Group ﻿

PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis ﻿

Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer ﻿

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study

Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer

Docetaxel (D) and cisplatin (C) induction chemotherapy followed by biweekly D and C with concurrent thoracic radiotherapy for stage iii nonsmall cell lung cancer (NSCLC). A galician lung cancer group study.

Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors

Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

Full-dose Cisplatin and Oral Vinorelbine Concomitant with Radiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: A Multi-center Phase II Study

Induction chemotherapy with docetaxel (D) and cisplatin (C) followed by concurrent thoracic radiotherapy with biweekly d and C for stage III non-small cell lung cancer (NSCLC) - A galician lung cancer group study

Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study)

Lung cancer symptoms at diagnosis: results of a nationwide registry study

Paclitaxel and irinotecan in platinum refractory or resistant patients with small cell lung cancer: Experience from the Galician Lung Cancer Group

PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis

Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer